ATE312628T1 - Kontrolliertes abbaubares polymer-biomolekül oder wirkstoffträger und verfahren zur synthese dieses trägers - Google Patents
Kontrolliertes abbaubares polymer-biomolekül oder wirkstoffträger und verfahren zur synthese dieses trägersInfo
- Publication number
- ATE312628T1 ATE312628T1 AT03728863T AT03728863T ATE312628T1 AT E312628 T1 ATE312628 T1 AT E312628T1 AT 03728863 T AT03728863 T AT 03728863T AT 03728863 T AT03728863 T AT 03728863T AT E312628 T1 ATE312628 T1 AT E312628T1
- Authority
- AT
- Austria
- Prior art keywords
- carrier
- synthesis
- degradable polymer
- present
- controlled degradable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Polyesters Or Polycarbonates (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Polyamides (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37816402P | 2002-05-14 | 2002-05-14 | |
US10/270,788 US20030215395A1 (en) | 2002-05-14 | 2002-10-11 | Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
PCT/US2003/015003 WO2003097107A2 (en) | 2002-05-14 | 2003-05-13 | Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE312628T1 true ATE312628T1 (de) | 2005-12-15 |
Family
ID=29423239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03728863T ATE312628T1 (de) | 2002-05-14 | 2003-05-13 | Kontrolliertes abbaubares polymer-biomolekül oder wirkstoffträger und verfahren zur synthese dieses trägers |
Country Status (11)
Country | Link |
---|---|
US (2) | US20030215395A1 (de) |
EP (1) | EP1503802B1 (de) |
JP (1) | JP4425128B2 (de) |
KR (1) | KR100994523B1 (de) |
CN (1) | CN1646174B (de) |
AT (1) | ATE312628T1 (de) |
AU (1) | AU2003234423A1 (de) |
CA (1) | CA2482458A1 (de) |
DE (1) | DE60302784T2 (de) |
ES (1) | ES2257672T3 (de) |
WO (1) | WO2003097107A2 (de) |
Families Citing this family (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
DK1301213T3 (en) * | 2000-07-21 | 2017-03-27 | Revance Therapeutics Inc | MULTI-COMPONENT SYSTEMS FOR BIOLOGICAL TRANSPORT |
US20040138154A1 (en) * | 2003-01-13 | 2004-07-15 | Lei Yu | Solid surface for biomolecule delivery and high-throughput assay |
US20070269891A9 (en) * | 2003-01-13 | 2007-11-22 | Yasunobu Tanaka | Solid surface with immobilized degradable cationic polymer for transfecting eukaryotic cells |
US20070155926A1 (en) * | 2003-03-28 | 2007-07-05 | Krzysztof Matyjaszewski | Degradable polymers |
US7332477B2 (en) * | 2003-07-10 | 2008-02-19 | Nitto Denko Corporation | Photocleavable DNA transfer agent |
JP4586022B2 (ja) * | 2003-09-29 | 2010-11-24 | 日東電工株式会社 | インビボポリヌクレオチド送達用生分解性ポリアセタール |
LT2985039T (lt) | 2004-03-03 | 2018-11-12 | Revance Therapeutics, Inc. | Botulino toksinų vietinis taikymas ir jų įvedimas per odą |
WO2005120546A2 (en) * | 2004-03-03 | 2005-12-22 | Essentia Biosystems, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
US7358223B2 (en) * | 2004-10-04 | 2008-04-15 | Nitto Denko Corporation | Biodegradable cationic polymers |
GB0422877D0 (en) * | 2004-10-14 | 2004-11-17 | Univ Glasgow | Bioactive polymers |
US8057821B2 (en) | 2004-11-03 | 2011-11-15 | Egen, Inc. | Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof |
CN101124316A (zh) * | 2004-12-17 | 2008-02-13 | 日东电工株式会社 | 用于转染真核细胞的固定的可降解阳离子聚合物 |
US20120269886A1 (en) | 2004-12-22 | 2012-10-25 | Nitto Denko Corporation | Therapeutic agent for pulmonary fibrosis |
HUE048419T2 (hu) | 2004-12-22 | 2020-08-28 | Nitto Denko Corp | Gyógyszerhordozó és kit gyógyszerhordozó kit fibrózis gátlására |
GB2422839B (en) * | 2005-01-11 | 2009-06-24 | Schlumberger Holdings | Degradable polymers for wellbore fluids and processes |
EP1856139B1 (de) * | 2005-03-03 | 2011-04-27 | Revance Therapeutics, Inc. | Zusammensetzungen und methoden zur topischen anwendung und zur transdermalen verabreichung eines oligopeptids |
JP2008531732A (ja) | 2005-03-03 | 2008-08-14 | ルバンス セラピュティックス インク. | ボツリヌス毒素の局所塗布及び経皮送達のための組成物及び方法 |
US9180196B2 (en) | 2005-03-11 | 2015-11-10 | The Regents Of The University Of Colorado, A Body Corporate | Photodegradable groups for tunable polymeric materials |
US8343710B1 (en) | 2005-03-11 | 2013-01-01 | The Regents Of The University Of Colorado, A Body Corporate | Photodegradable groups for tunable polymeric materials |
JPWO2006098463A1 (ja) * | 2005-03-14 | 2008-08-28 | 株式会社進化創薬 | ポリ核酸結合物質 |
US7674452B2 (en) * | 2005-03-16 | 2010-03-09 | Nitto Denko Corporation | Polymer coating of cells |
KR101504622B1 (ko) * | 2005-04-29 | 2015-03-20 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | 고차가지구조 고분자 및 그들의 응용 |
JP4870941B2 (ja) * | 2005-05-09 | 2012-02-08 | 公立大学法人大阪府立大学 | 高分子化合物 |
US7588754B2 (en) * | 2005-05-10 | 2009-09-15 | Nitto Denko Corporation | Biodegradable polyacetals and methods |
US20060263328A1 (en) * | 2005-05-19 | 2006-11-23 | Sang Van | Hydrophilic polymers with pendant functional groups and method thereof |
EP2476756A1 (de) | 2005-06-15 | 2012-07-18 | Massachusetts Institute of Technology | Aminhaltige Lipide und ihre Verwendungen |
WO2007019461A2 (en) * | 2005-08-08 | 2007-02-15 | Angstrom Medica, Inc. | Cement products and methods of making and using the same |
JP4962931B2 (ja) * | 2005-11-16 | 2012-06-27 | 公立大学法人大阪府立大学 | ポリアミドアミンデンドロン脂質を含む遺伝子等運搬媒体組成物 |
WO2007059528A2 (en) * | 2005-11-17 | 2007-05-24 | Revance Therapeutics, Inc. | Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins |
US9572886B2 (en) | 2005-12-22 | 2017-02-21 | Nitto Denko Corporation | Agent for treating myelofibrosis |
DE102006008701A1 (de) * | 2006-02-23 | 2007-08-30 | Qiagen Gmbh | Ein Verfahren zur Herstellung einer transformierten Zelle |
US7700541B2 (en) * | 2006-04-06 | 2010-04-20 | Nitto Denko Corporation | Biodegradable cationic polymers |
CN100549044C (zh) * | 2006-11-16 | 2009-10-14 | 南京慧基生物技术有限公司 | 可生物降解的交联聚乙烯亚胺及其应用 |
KR20090096735A (ko) * | 2006-12-29 | 2009-09-14 | 레반스 테라퓨틱스, 아이엔씨. | Hiv-tat로부터 유래된 폴리펩티드 단편에 의해 안정화된 보툴리눔 독소의 국소 적용 및 경피 전달용 조성물 및 방법 |
WO2008082885A2 (en) * | 2006-12-29 | 2008-07-10 | Revance Therapeutics, Inc. | Transport molecules using reverse sequence hiv-tat polypeptides |
TWI407971B (zh) | 2007-03-30 | 2013-09-11 | Nitto Denko Corp | Cancer cells and tumor-related fibroblasts |
GB2463198B (en) | 2007-05-23 | 2013-05-22 | Univ Carnegie Mellon | Hybrid particle composite structures with reduced scattering |
US20080312174A1 (en) * | 2007-06-05 | 2008-12-18 | Nitto Denko Corporation | Water soluble crosslinked polymers |
HUE031136T2 (en) * | 2007-07-26 | 2017-07-28 | Revance Therapeutics Inc | Antimicrobial peptide and preparations |
WO2009029734A2 (en) * | 2007-08-28 | 2009-03-05 | Pioneer Surgical Technology, Inc. | Cement products and methods of making and using the same |
JP2010539245A (ja) | 2007-09-14 | 2010-12-16 | 日東電工株式会社 | 薬物担体 |
US8703194B2 (en) | 2007-11-02 | 2014-04-22 | Agency For Science, Technology And Research | Stimulus-responsive biodegradable polymers and methods of preparation |
EP2215147B1 (de) * | 2007-11-07 | 2014-04-16 | University of Utah Research Foundation | Spaltbare modifikationen von reduzierbaren poly(amidoethylenimin)en zur verbesserung der nucleotidzufuhr |
US20090130752A1 (en) * | 2007-11-07 | 2009-05-21 | University Of Utah Research Foundation | Biodegradable poly(disulfide amine)s for gene delivery |
JP5619341B2 (ja) * | 2007-11-30 | 2014-11-05 | エイジェンシー フォー サイエンス, テクノロジー アンド リサーチAgency For Science,Technology And Research | 刺激応答型生分解性高分子及びその製造方法 |
JP2011514423A (ja) * | 2008-03-14 | 2011-05-06 | エーゲン、インコーポレイテッド | 生分解性架橋分枝状ポリ(アルキレンイミン) |
KR100961280B1 (ko) * | 2008-05-21 | 2010-06-03 | 한국생명공학연구원 | 형광특성이 향상된 풀러렌-실리카 나노입자, 이의 제조방법및 이의 용도 |
MX2011004859A (es) | 2008-11-07 | 2011-08-03 | Massachusetts Inst Technology | Lipidoides de aminoalcohol y usos de los mismos. |
WO2010132876A1 (en) * | 2009-05-15 | 2010-11-18 | Arizona Board Of Regents For And On Behalf Of Arizona State University | Polymers for delivering a substance into a cell |
PT2506857T (pt) | 2009-12-01 | 2018-05-14 | Translate Bio Inc | Entrega de arnm para o acréscimo de proteínas e enzimas em doenças genéticas humanas |
US9193827B2 (en) | 2010-08-26 | 2015-11-24 | Massachusetts Institute Of Technology | Poly(beta-amino alcohols), their preparation, and uses thereof |
CN102010508B (zh) * | 2010-10-19 | 2012-10-03 | 北京大学 | 一种阳离子聚合物及其制备方法和应用 |
WO2012091965A1 (en) | 2010-12-17 | 2012-07-05 | Carnegie Mellon University | Electrochemically mediated atom transfer radical polymerization |
US20120202890A1 (en) * | 2011-02-08 | 2012-08-09 | Nian Wu | Polymer-carbohydrate-lipid conjugates |
KR101459185B1 (ko) * | 2011-03-25 | 2014-11-07 | 서울대학교산학협력단 | 스페르민 공중합체 및 이를 핵산 전달체로 이용하는 유전자 치료 |
EP2691443B1 (de) | 2011-03-28 | 2021-02-17 | Massachusetts Institute of Technology | Konjugierte lipomers und ihre verwendung |
TR201910686T4 (tr) | 2011-06-08 | 2019-08-21 | Translate Bio Inc | Mrna iletimine yönelik lipit nanopartikül bileşimleri ve yöntemler. |
US8883177B2 (en) | 2011-06-28 | 2014-11-11 | Nian Wu | Pharmaceutical compositions for parenteral administration |
EP2747753B1 (de) | 2011-08-22 | 2023-03-29 | Carnegie Mellon University | Radikalische atomtransfer-polymerisation unter biologisch verträglichen bedingungen |
EP4074694A1 (de) | 2011-10-27 | 2022-10-19 | Massachusetts Institute Of Technology | Aminosäure-, peptid- und polypeptide-lipoide, isomere, zusammensetzungen und verwendungen davon |
US20150267192A1 (en) | 2012-06-08 | 2015-09-24 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
WO2014028487A1 (en) | 2012-08-13 | 2014-02-20 | Massachusetts Institute Of Technology | Amine-containing lipidoids and uses thereof |
US9109087B2 (en) * | 2012-09-13 | 2015-08-18 | International Business Machines Corporation | Low molecular weight branched polyamines for delivery of biologically active materials |
MX370929B (es) | 2012-10-28 | 2020-01-08 | Revance Therapeutics Inc | Composiciones y usos de las mismas para el tratamiento seguro de la rinitis. |
KR101460204B1 (ko) * | 2013-01-08 | 2014-11-10 | 한국과학기술원 | 친수성 핵산 유전자를 유기용매에 가용화시키고, 이를 소수성 미립자에 봉입한 제어방출형 유전자 전달용 복합체와 이의 제조방법 |
EA201591229A1 (ru) | 2013-03-14 | 2016-01-29 | Шир Хьюман Дженетик Терапис, Инк. | Способы очистки матричной рнк |
PL2968586T3 (pl) | 2013-03-14 | 2019-01-31 | Translate Bio, Inc. | Kompozycje mrna cftr i związne z nimi sposoby i zastosowania |
US9315472B2 (en) | 2013-05-01 | 2016-04-19 | Massachusetts Institute Of Technology | 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof |
EP4276176A3 (de) | 2013-10-22 | 2024-01-10 | Translate Bio, Inc. | Mrna-therapie für argininosuccinat-synthase-mangel |
EP3060258A1 (de) | 2013-10-22 | 2016-08-31 | Shire Human Genetic Therapies, Inc. | Mrna-therapie für phenylketonurie |
NZ718817A (en) | 2013-10-22 | 2020-07-31 | Massachusetts Inst Technology | Lipid formulations for delivery of messenger rna |
JP6466637B2 (ja) * | 2013-11-28 | 2019-02-06 | ソマール株式会社 | 糖鎖含有ポリマー、および、糖鎖含有ポリマー複合体 |
EA201691696A1 (ru) | 2014-04-25 | 2017-03-31 | Шир Хьюман Дженетик Терапис, Инк. | Способы очистки матричной рнк |
AU2015266764B2 (en) | 2014-05-30 | 2019-11-07 | Translate Bio, Inc. | Biodegradable lipids for delivery of nucleic acids |
FR3022544B1 (fr) * | 2014-06-23 | 2018-01-05 | Arkema France | Oligomeres acryles multifonctionnels de structure ramifiee, par polyaddition entre amines et acrylates multifonctionnels. |
CN106795142B (zh) | 2014-06-24 | 2022-11-04 | 川斯勒佰尔公司 | 用于递送核酸的立体化学富集组合物 |
WO2016004202A1 (en) | 2014-07-02 | 2016-01-07 | Massachusetts Institute Of Technology | Polyamine-fatty acid derived lipidoids and uses thereof |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
EP3034539A1 (de) * | 2014-12-19 | 2016-06-22 | Ethris GmbH | Zusammensetzungen zur Einführung von Nukleinsäure in Zellen |
CN104561067A (zh) * | 2014-12-24 | 2015-04-29 | 广东省人民医院 | 一种安全高效的蛋白质转染进入细胞的载体 |
US9982070B2 (en) | 2015-01-12 | 2018-05-29 | Carnegie Mellon University | Aqueous ATRP in the presence of an activator regenerator |
SI3310764T1 (sl) | 2015-06-19 | 2023-06-30 | Massachusetts Institute Of Technology | Z alkenilom substituirani 2,5-piperazindioni in njihova uporaba v sestavkih za dostavo sredstva subjektu ali celici |
PL3334462T3 (pl) | 2015-08-14 | 2022-05-09 | RemeGen Biosciences, Inc. | Kowalencyjne linkery w koniugatach przeciwciało-lek oraz sposoby ich wytwarzania i zastosowania |
JP7236195B2 (ja) | 2016-04-14 | 2023-03-09 | ベニテック アイピー ホールディングス インコーポレーテッド | 眼咽頭筋ジストロフィー(opmd)の処置のための試薬およびその使用 |
CN106146834B (zh) * | 2016-06-24 | 2018-12-18 | 浙江大学 | 一种具有酯酶响应的阳离子聚合物 |
GB2551979A (en) | 2016-06-30 | 2018-01-10 | Rs Arastirma Egitim Danismanlik Llac Sanayi Ticaret Ltd | Cleavable polymer drug conjugates |
GB2556055B (en) | 2016-11-16 | 2022-03-23 | Rs Arastirma Egitim Danismanlik Ilac Sanayi Ticaret Ltd Sti | Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments |
CN106755111A (zh) * | 2017-01-11 | 2017-05-31 | 山东省肿瘤防治研究院 | 一种富含羟基的纳米基因载体及其制备方法与应用 |
US11174325B2 (en) | 2017-01-12 | 2021-11-16 | Carnegie Mellon University | Surfactant assisted formation of a catalyst complex for emulsion atom transfer radical polymerization processes |
MA47603A (fr) | 2017-02-27 | 2020-01-01 | Translate Bio Inc | Nouvel arnm cftr à codons optimisés |
WO2018213476A1 (en) | 2017-05-16 | 2018-11-22 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
CN109134855B (zh) * | 2018-07-23 | 2021-03-23 | 安徽大学 | 一种酸敏感的聚酰胺胺的阳离子聚合物poeamam及其制备方法和应用 |
CA3108544A1 (en) | 2018-08-24 | 2020-02-27 | Translate Bio, Inc. | Methods for purification of messenger rna |
EP3798250A1 (de) | 2019-09-25 | 2021-03-31 | University College Dublin | Hyperverzweigte kationische polymere, die als nukleinsäureabgabevektoren für die transfektion geeignet sind |
CN111647166B (zh) * | 2020-06-29 | 2022-08-02 | 苏州大学 | 可降解超支化聚合物 |
CN114904003B (zh) * | 2021-02-09 | 2023-09-29 | 广州立得生物医药科技有限公司 | 可电离的阳离子脂质类似物材料在作为核酸药物递送载体或转染试剂中的应用 |
CN114874294B (zh) * | 2022-03-25 | 2024-01-30 | 圣诺生物医药技术(苏州)有限公司 | 一种多肽化合物、多肽脂质纳米递送系统及其应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6509032B1 (en) * | 1991-08-28 | 2003-01-21 | Mcmaster University | Cationic amphiphiles |
US5919455A (en) * | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
KR100371649B1 (ko) * | 1994-08-12 | 2003-05-22 | 가오가부시끼가이샤 | 개선된초흡수성중합체의제조방법 |
CA2256900A1 (en) * | 1996-05-29 | 1997-12-04 | Xiao-Ying Meng | Cationic polymer/lipid nucleic acid delivery vehicles |
US6060534A (en) * | 1996-07-11 | 2000-05-09 | Scimed Life Systems, Inc. | Medical devices comprising ionically and non-ionically crosslinked polymer hydrogels having improved mechanical properties |
US5925379A (en) * | 1997-03-27 | 1999-07-20 | Geltex Pharmaceuticals, Inc. | Interpenetrating polymer networks for sequestration of bile acids |
DE19726186A1 (de) * | 1997-06-20 | 1998-12-24 | Boehringer Ingelheim Int | Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen |
KR100219918B1 (ko) * | 1997-07-03 | 1999-09-01 | 김윤 | 대장선택적 약물전달용 조성물 |
US6290947B1 (en) * | 1997-09-19 | 2001-09-18 | Geltex Pharmaceuticals, Inc. | Ionic polymers as toxin-binding agents |
US6072101A (en) * | 1997-11-19 | 2000-06-06 | Amcol International Corporation | Multicomponent superabsorbent gel particles |
KR100520183B1 (ko) * | 1999-08-23 | 2005-10-10 | 주식회사 하이닉스반도체 | 두 개의 이중결합을 가지는 가교제를 단량체로 포함하는 포토레지스트용 공중합체 |
US6696038B1 (en) * | 2000-09-14 | 2004-02-24 | Expression Genetics, Inc. | Cationic lipopolymer as biocompatible gene delivery agent |
WO2003078576A2 (en) * | 2002-03-12 | 2003-09-25 | Nitto Denko Corporation | Vector for transfection of eukaryotic cells |
-
2002
- 2002-10-11 US US10/270,788 patent/US20030215395A1/en not_active Abandoned
-
2003
- 2003-05-13 AU AU2003234423A patent/AU2003234423A1/en not_active Abandoned
- 2003-05-13 JP JP2004505102A patent/JP4425128B2/ja not_active Expired - Fee Related
- 2003-05-13 AT AT03728863T patent/ATE312628T1/de not_active IP Right Cessation
- 2003-05-13 WO PCT/US2003/015003 patent/WO2003097107A2/en active IP Right Grant
- 2003-05-13 EP EP03728863A patent/EP1503802B1/de not_active Expired - Lifetime
- 2003-05-13 CA CA002482458A patent/CA2482458A1/en not_active Abandoned
- 2003-05-13 ES ES03728863T patent/ES2257672T3/es not_active Expired - Lifetime
- 2003-05-13 DE DE60302784T patent/DE60302784T2/de not_active Expired - Lifetime
- 2003-05-13 KR KR1020047016453A patent/KR100994523B1/ko not_active IP Right Cessation
- 2003-05-13 CN CN038083191A patent/CN1646174B/zh not_active Expired - Fee Related
-
2006
- 2006-02-27 US US11/364,596 patent/US20060147376A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1503802A2 (de) | 2005-02-09 |
JP4425128B2 (ja) | 2010-03-03 |
KR100994523B1 (ko) | 2010-11-15 |
WO2003097107A3 (en) | 2004-01-22 |
US20060147376A1 (en) | 2006-07-06 |
DE60302784T2 (de) | 2006-07-06 |
EP1503802B1 (de) | 2005-12-14 |
US20030215395A1 (en) | 2003-11-20 |
JP2005532323A (ja) | 2005-10-27 |
CN1646174B (zh) | 2010-12-08 |
AU2003234423A1 (en) | 2003-12-02 |
WO2003097107A2 (en) | 2003-11-27 |
ES2257672T3 (es) | 2006-08-01 |
KR20050006161A (ko) | 2005-01-15 |
CN1646174A (zh) | 2005-07-27 |
DE60302784D1 (de) | 2006-01-19 |
CA2482458A1 (en) | 2003-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE312628T1 (de) | Kontrolliertes abbaubares polymer-biomolekül oder wirkstoffträger und verfahren zur synthese dieses trägers | |
Carlini et al. | Biosynthetic polymers as functional materials | |
Liu et al. | Fabrication of 3D-printed fish-gelatin-based polymer hydrogel patches for local delivery of pegylated liposomal doxorubicin | |
CY1111894T1 (el) | Προϊοντα συζευξης auristatin και χρηση αυτων για θεραπεια καρκινου, αυτοανοσης ασθενειας ή μολυσματωδους ασθενειας | |
CY1111174T1 (el) | Σχετιζομενα με ογκους πεπτιδια δεσμευμενα σε μορια mhc | |
Tiwari et al. | Bioengineered nanomaterials | |
CY1106601T1 (el) | Χρηση του παραγωγου κουιναζολινης zd6474 συνδυασμενου με γκεμσιταμπινη και προαιρετικα με ιοντιζουσα ακτινοβολια στη θεραπεια του καρκινου | |
CY1107881T1 (el) | Τροποποιημενα πεπτιδια ως θεραπευτικοι παραγοντες | |
DE69735851D1 (de) | Verfahren zur aktivierung von menschlichen, antigen-aktivierenden zellen, aktivierte menschliche, antigen-aktivierende zellen und anwendungen derselben | |
CY1114863T1 (el) | Στερεο παρασκευασμα | |
BRPI0311822B8 (pt) | composição farmacêutica para o tratamento de câncer | |
HUP0400231A2 (hu) | Rákos megbetegedések kezelésében különösen hasznos, immundecepcióra szolgáló eljárások és gyógyszerkészítmények | |
WO2017141204A3 (en) | Biguanide grafted / modified biopolymers as drug delivery vehicles | |
Yoo et al. | A local drug delivery system based on visible light-cured glycol chitosan and doxorubicin⋅ hydrochloride for thyroid cancer treatment in vitro and in vivo | |
CY1109120T1 (el) | Φαρμακευτικη συνθεση βινφλουνινης που προοριζεται για παρεντερικη χορηγηση, μεθοδος παρασκευης και χρησης | |
NO20055209L (no) | Peptabody for cancerbehandling | |
Bhatt et al. | Plasma modification techniques for natural polymer-based drug delivery systems | |
Cuzzubbo et al. | Applications of melanin and melanin-like nanoparticles in cancer therapy: A review of recent advances | |
PH12015501467A1 (en) | Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof | |
Çalimsiz et al. | Synthesis of N-Fmoc-(2 S, 3 S, 4 R)-3, 4-dimethylglutamine: an application of lanthanide-catalyzed transamidation | |
Paris et al. | Exploiting protected maleimides to modify oligonucleotides, peptides and peptide nucleic acids | |
CY1107231T1 (el) | Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης | |
Dispenza et al. | Micro-to nanoscale bio-hybrid hydrogels engineered by ionizing radiation | |
Okamoto et al. | Efficient substitution reaction from cysteine to the serine residue of glycosylated polypeptide: repetitive peptide segment ligation strategy and the synthesis of glycosylated tetracontapeptide having acid labile sialyl-TN antigens | |
Pryyma et al. | Rapid, high-yielding solid-phase synthesis of cathepsin-B cleavable linkers for targeted cancer therapeutics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |